Clinical Trial Update: A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD [Phase 1, Phase 2]

View source ↗

Summary

A longitudinal Phase 1/2 trial evaluating ACTEMRA (tocilizumab) as monotherapy in highly active neuromyelitis optica spectrum disorders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Devic Disease
• Neuromyelitis Optica
• Neuromyelitis Optica Spectrum Disorders

Drugs mentioned

• Actemra (tocilizumab)

Snippet

Sponsor: Fu-Dong Shi | Conditions: Neuromyelitis Optica Spectrum Disorders, Neuromyelitis Optica | Phase 1, Phase 2 | Status: COMPLETED